4 Reasons Nonpharma Attys Should Know Pay-For-Delay Law

Law360, New York (April 21, 2016, 9:44 PM EDT) -- Pharmaceutical antitrust lawyers have long been riveted by cases accusing branded-drug makers of paying generic-drug companies to postpone competition, but attorneys focused on other industries might want to start paying closer attention to how pay-for-delay decisions could affect their clients, experts say.

Pay-for-delay litigation has been essentially limited to the life sciences sector so far, but there is no guarantee that it will stay that way. And even if nonpharmaceutical companies aren't named as defendants in pay-for-delay cases, they might have a strong interest in some...
To view the full article, register now.